Publications by authors named "Iturbe Julian"
Article Synopsis
- The study focuses on women diagnosed with brain metastases at the same time as breast cancer, which is a rare and complex situation.
- In the analysis of 740 patients, the median overall survival was found to be 10 months, with only 20.7% surviving at 3 years; tumor subtype significantly influenced survival rates.
- Key findings indicated that triple-negative breast cancer had the shortest median survival of 6 months, while the HR+/HER2+ subtype had the longest, at 22 months; additional factors affecting survival included age, type of tumor histology, presence of liver metastases, and marital status.
Article Synopsis
- Male breast cancer (MaBC) is not well understood, especially regarding the treatment and outcomes for early-stage patients; this study analyzed characteristics, treatments, and survival rates of men with early-stage MaBC.
- The study included 1263 men diagnosed between 1988 and 2012, showing a 5-year overall survival (OS) rate of 85.1%, with older age, higher tumor grades, lack of surgery, and no lymph node examination correlating with poorer outcomes.
- Findings suggest that while men with early MaBC have generally good survival rates, there is a need to reconsider the high rates of mastectomy and extensive lymph node examination since breast conservation and fewer lymph nodes examined yield similar survival rates.
Article Synopsis
- - The study investigates the impact of CD44 and Lewis Y antigen (LeY) on therapy resistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC), showing that these markers relate to tumor behavior and patient outcomes.
- - Data from 126 patients was analyzed, revealing that advanced disease and expression of LeY were linked to poorer survival rates in those treated with standard radiochemotherapy based on cisplatin.
- - While coexpression of CD44 and LeY was not associated with worse outcomes overall, LeY expression specifically indicated shorter disease-free and overall survival in patients receiving radiochemotherapy.
Prognostic factors in male breast cancer: a population-based study.
Breast Cancer Res Treat
April 2016
Article Synopsis
- The study investigated prognostic factors in male breast cancer (MaBC) by analyzing data from 2992 patients diagnosed between 2003 and 2012.
- Results showed that most MaBC cases were ductal, hormone receptor-positive, and early-stage, while grade I tumors were rare.
- Key findings indicated that older age, higher tumor grades, advanced disease stage, lack of surgery or radiotherapy, ER negativity, and being unmarried were linked to shorter overall survival.
Article Synopsis
- This study evaluates the roles of ERCC1 and TUBB3 as predictive and prognostic factors in patients with locally advanced cervical squamous cell carcinoma (LACSCC) who are undergoing different chemoradiotherapy regimens.
- High expressions of ERCC1 and TUBB3 were found in a significant portion of patients, with ERCC1 linked to advanced disease stages and poorer survival outcomes in those receiving cisplatin treatment.
- The findings suggest that while ERCC1 expression can indicate patient prognosis, TUBB3 does not influence survival outcomes in patients treated with antimicrotubule therapies.
Article Synopsis
- - The study aims to assess the characteristics and prognostic implications of different tumor subtypes in male breast cancer (MaBC), specifically analyzing data from 960 patients recorded between 2010 and 2012.
- - Patients were categorized into four subtypes based on hormone receptor (HR) and HER2 status, revealing that triple-negative (TN) patients tended to be younger and had poorer outcomes compared to other subtypes.
- - Univariate and multivariate analyses showed that factors like HER2 positivity, tumor stage, and being older significantly impacted overall survival (OS), emphasizing that tumor subtype plays a vital role in prognosis alongside age and stage.
Article Synopsis
- * After analyzing data from 126 patients over a median follow-up of 4.5 years, the two chemotherapy regimens exhibited similar objective response rates and survival outcomes, with no significant differences in disease-free or overall survival.
- * The study found that the number of pathologically involved lymph nodes was the strongest predictor of survival, and while both regimens were tolerated, CMF had more severe blood-related side effects, while FAC was linked to more hair loss.
Most cases of breast cancer are diagnosed at early stage of disease; therefore, treatment is oriented to increase the disease-free interval (DFI) and overall survival (OS). The prognosis, in comparison with other malignancies, has improved in the last decades as a result of mammographic screening. The aim of the study was to report the incidence of local and distant recurrence, DFI and OS in patients (pts) with stage I and stage II breast cancer over a period of 26 years divided into three groups.
View Article and Find Full Text PDF